IDEAYA Biosciences, Inc. filed a registration statement on November 3, 2026, to register an additional 3,000,000 shares of common stock issuable under its 2023 Employment Inducement Award Plan, as amended.

Key Highlights

  • Additional shares registered: 3,000,000 shares of common stock, par value $0.0001 per share, added to the 2023 Employment Inducement Award Plan.
  • Prior reserve: The Inducement Plan had previously reserved 4,000,000 shares of common stock before this registration.
  • Board-adopted amendment: The most recent plan amendment, effective August 19, 2026, was adopted by the board of directors without stockholder approval, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • Prior registrations: Shares under the plan were previously registered on March 7, 2023 (File No. 333-270334), August 6, 2024 (File No. 333-281301), and August 5, 2025 (File No. 333-289256).
  • Filer classification: IDEAYA Biosciences is identified in the filing as a large accelerated filer.
  • Signing officers: Yujiro Hata, President and Chief Executive Officer, and Joshua Bleharski, Ph.D., Chief Financial Officer, signed the registration statement on November 3, 2026.

IDEAYA Biosciences Expands Inducement Equity Pool With August 2026 Plan Amendment

According to the filing, IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a biosciences company incorporated in Delaware and headquartered at 5000 Shoreline Court, Suite 300, South San Francisco, California, registered an additional 3,000,000 shares of common stock under its 2023 Employment Inducement Award Plan, as amended. The registration was submitted pursuant to General Instruction E of the Securities Act of 1933, which permits the company to incorporate by reference the contents of its prior related registration statements rather than restating all information from scratch.

The filing states that the Inducement Plan had previously reserved 4,000,000 shares before this registration, and that the plan has been amended multiple times, including amendments effective June 25, 2024, May 21, 2025, and most recently August 19, 2026. The company disclosed that the Inducement Plan was adopted and each amendment was approved by the board of directors without stockholder approval, in reliance on Nasdaq Listing Rule 5635(c)(4), which permits inducement grants to new employees outside of stockholder-approved plans under specified conditions.

The registration statement incorporates by reference the company's Annual Report on Form 10-K for the year ended December 31, 2025, filed February 17, 2026, as well as Quarterly Reports for the periods ended March 31, 2026, June 30, 2026, and September 30, 2026. An opinion from Latham and Watkins LLP and a consent from the company's independent registered public accounting firm were filed as exhibits alongside the registration statement.

What Was Disclosed

IDEAYA Biosciences filed to register 3,000,000 additional shares of common stock under its 2023 Employment Inducement Award Plan on November 3, 2026, following a board-approved amendment effective August 19, 2026, and without stockholder approval, as permitted under Nasdaq Listing Rule 5635(c)(4).